Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) surged nearly 6% in early trading today, following the company\u2019s announcement of positive updates on its vatiquinone Friedreich ataxia (FA) program. The company reported highly significant results from two long-term extension studies, showing a durable treatment benefit in slowing disease progression. This news sent the stock up as investors reacted positively to the development.<\/p>\n
PTC Therapeutics\u2019 CEO, Matthew B. Klein, M.D., expressed optimism about the results, emphasizing the strong safety profile of vatiquinone and its potential as a meaningful therapy, particularly for children and adolescents with Friedreich ataxia who currently lack approved treatment options. The company plans to submit a New Drug Application (NDA) to the FDA by the end of the year.<\/p>\n
The 144-week MOVE-FA extension study demonstrated a 50% slowing of disease progression compared to a matched cohort, with a 3.7-point benefit on the modified Friedreich Ataxia Rating Scale (mFARS). These results build upon earlier findings from a 72-week placebo-controlled trial. The treatment was also well tolerated, with no serious adverse events reported.<\/p>\n
As PTC continues to align with the FDA on its submission strategy, the market has responded with increased trading activity, reflecting growing optimism about vatiquinone\u2019s potential approval.<\/p>\n","protected":false},"excerpt":{"rendered":"
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) surged nearly 6% in early trading today, following the company\u2019s announcement of positive\u2026<\/p>\n","protected":false},"author":432,"featured_media":56342,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[20063],"class_list":["post-56339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets","tag-ptc-therapeutics"],"reading_time":"1 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/56339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/432"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=56339"}],"version-history":[{"count":0,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/56339\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/56342"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=56339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=56339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=56339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}